Literature DB >> 21812918

Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.

T B Dunn1, H Noreen, K Gillingham, D Maurer, O G Ozturk, T L Pruett, R A Bray, H M Gebel, A J Matas.   

Abstract

Single-antigen bead (SAB) testing permits reassessment of immunologic risk for kidney transplantation. Traditionally, high panel reactive antibody (PRA), retransplant and deceased donor (DD) grafts have been associated with increased risk. We hypothesized that this risk was likely mediated by (unrecognized) donor-specific antibody (DSA). We grouped 587 kidney transplants using clinical history and single-antigen bead (SAB) testing of day of transplant serum as (1) unsensitized; PRA = 0 (n = 178), (2) third-party sensitized; no DSA (n = 363) or (3) donor sensitized; with DSA (n = 46), and studied rejection rates, death-censored graft survival (DCGS) and risk factors for rejection. Antibody-mediated rejection (AMR) rates were increased with DSA (p < 0.0001), but not with panel reactive antibody (PRA) in the absence of DSA. Cell-mediated rejection (CMR) rates were increased with DSA (p < 0.005); with a trend to increased rates when PRA>0 in the absence of DSA (p = 0.08). Multivariate analyses showed risk factors for AMR were DSA, worse HLA matching, and female gender; for CMR: DSA, PRA>0 and worse HLA matching. AMR and CMR were associated with decreased DCGS. The presence of DSA is an important predictor of rejection risk, in contrast to traditional risk factors. Further development of immunosuppressive protocols will be facilitated by stratification of rejection risk by donor sensitization. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812918      PMCID: PMC3184338          DOI: 10.1111/j.1600-6143.2011.03640.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  34 in total

1.  Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.

Authors:  Jonathan P Pearl; Jeremy Parris; Douglas A Hale; Steven C Hoffmann; Wendy B Bernstein; Kelly L McCoy; S John Swanson; Roslyn B Mannon; Mario Roederer; Allan D Kirk
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

2.  C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings.

Authors:  M Haas; M H Rahman; L C Racusen; E S Kraus; S M Bagnasco; D L Segev; C E Simpkins; D S Warren; K E King; A A Zachary; R A Montgomery
Journal:  Am J Transplant       Date:  2006-08       Impact factor: 8.086

Review 3.  HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation.

Authors:  Adriana Zeevi; Alin Girnita; Rene Duquesnoy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Clinical relevance of anti-HLA antibodies pre and post transplant.

Authors:  R H Kerman; C G Orosz; M I Lorber
Journal:  Am J Med Sci       Date:  1997-05       Impact factor: 2.378

5.  Kidney transplantation in patients with antibodies against donor HLA class II.

Authors:  H S Pollinger; M D Stegall; J M Gloor; S B Moore; S R Degoey; N A Ploeger; W D Park; H S Pollinger; M D Stegall; J M Gloor; S B Moore; S R Degoey; N A Ploeger; W D Park
Journal:  Am J Transplant       Date:  2007-02-09       Impact factor: 8.086

6.  The Banff 97 working classification of renal allograft pathology.

Authors:  L C Racusen; K Solez; R B Colvin; S M Bonsib; M C Castro; T Cavallo; B P Croker; A J Demetris; C B Drachenberg; A B Fogo; P Furness; L W Gaber; I W Gibson; D Glotz; J C Goldberg; J Grande; P F Halloran; H E Hansen; B Hartley; P J Hayry; C M Hill; E O Hoffman; L G Hunsicker; A S Lindblad; Y Yamaguchi
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

7.  The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody.

Authors:  P F Halloran; J Schlaut; K Solez; N S Srinivasa
Journal:  Transplantation       Date:  1992-03       Impact factor: 4.939

8.  Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching.

Authors:  C F Bryan; K A Baier; P W Nelson; A M Luger; J Martinez; G E Pierce; G Ross; C F Shield; B A Warady; M I Aeder; T S Helling; N Muruve
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

9.  Kidney retransplantation in the cyclosporine era.

Authors:  R J Stratta; C S Oh; H W Sollinger; J D Pirsch; M Kalayoglu; F O Belzer
Journal:  Transplantation       Date:  1988-01       Impact factor: 4.939

10.  Sensitization and crossmatching in renal transplantation.

Authors:  P Koka; J M Cecka
Journal:  Clin Transpl       Date:  1989
View more
  53 in total

1.  Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes: Results From Clinical Trials in Organ Transplantation-17.

Authors:  Geovani Faddoul; Girish N Nadkarni; Nancy D Bridges; Jens Goebel; Donald E Hricik; Richard Formica; Madhav C Menon; Yvonne Morrison; Barbara Murphy; Kenneth Newell; Peter Nickerson; Emilio D Poggio; David Rush; Peter S Heeger
Journal:  Transplantation       Date:  2018-04       Impact factor: 4.939

2.  Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Antibodies: Problems and Solutions.

Authors:  Vadim Jucaud; Mepur H Ravindranath; Paul I Terasaki
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 3.  Identification and therapeutic management of highly sensitized patients undergoing renal transplantation.

Authors:  Lu Huber; Nils Lachmann; Michael Dürr; Mareen Matz; Lutz Liefeldt; Hans-H Neumayer; Constanze Schönemann; Klemens Budde
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 4.  Donor-specific antibodies adversely affect kidney allograft outcomes.

Authors:  Sumit Mohan; Amudha Palanisamy; Demetra Tsapepas; Bekir Tanriover; R John Crew; Geoffrey Dube; Lloyd E Ratner; David J Cohen; Jai Radhakrishnan
Journal:  J Am Soc Nephrol       Date:  2012-11-15       Impact factor: 10.121

5.  Isolated endarteritis and kidney transplant survival: a multicenter collaborative study.

Authors:  Banu Sis; Serena M Bagnasco; Lynn D Cornell; Parmjeet Randhawa; Mark Haas; Belinda Lategan; Alex B Magil; Andrew M Herzenberg; Ian W Gibson; Michael Kuperman; Kotaro Sasaki; Edward S Kraus
Journal:  J Am Soc Nephrol       Date:  2014-11-07       Impact factor: 10.121

6.  Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.

Authors:  Mario Carmellini; Valter Garcia; Zailong Wang; Marcela Vergara; Graeme Russ
Journal:  J Nephrol       Date:  2015-02-24       Impact factor: 3.902

7.  The role of donor-specific HLA alloantibodies in liver transplantation.

Authors:  J G O'Leary; A J Demetris; L S Friedman; H M Gebel; P F Halloran; A D Kirk; S J Knechtle; S V McDiarmid; A Shaked; P I Terasaki; K J Tinckam; S J Tomlanovich; K J Wood; E S Woodle; A A Zachary; G B Klintmalm
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

8.  A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A.

Authors:  Anne-Kristina Frobel; Mats O Karlsson; Janne T Backman; Kalle Hoppu; Erik Qvist; Paula Seikku; Hannu Jalanko; Christer Holmberg; Ron J Keizer; Samuel Fanta; Siv Jönsson
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 9.  Ischaemic and inflammatory injury in renal graft from brain death donation: an update review.

Authors:  Anthony Fung; Hailin Zhao; Bob Yang; Qingqian Lian; Daqing Ma
Journal:  J Anesth       Date:  2016-01-08       Impact factor: 2.078

Review 10.  The paradoxical functions of B cells and antibodies in transplantation.

Authors:  Marilia I Cascalho; Brian J Chen; Mandy Kain; Jeffrey L Platt
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.